Immunomodulatory intervention with interferon-γ in Escherichia coli pyelonephritis

J Urol. 2014 Aug;192(2):600-6. doi: 10.1016/j.juro.2014.03.092. Epub 2014 Mar 25.

Abstract

Purpose: We investigated the efficacy of recombinant human interferon-γ in experimental pyelonephritis due to Escherichia coli.

Materials and methods: Pyelonephritis was induced by intrapelvic inoculation of bacteria after ureteral ligation in 38 rabbits assigned to 1 of 3 groups, including group 1-16 controls, group 2-14 rabbits treated with intravenous recombinant human interferon-γ and group 3-8 rabbits treated with intravenous recombinant human interferon-γ plus amikacin. Bacterial counts, cytokines and malondialdehyde were measured in blood. Peripheral blood mononuclear cells were isolated to measure TNFα transcripts, cytokine stimulation and apoptosis. Survival was recorded, and the tissue bacterial load and myeloperoxidase activity were measured after sacrifice.

Results: The mortality rate in groups 1, 2 and 3 was 66.7%, 25% and 12.5%, respectively. The circulating bacterial count and tissue bacterial load were less in group 2 than in group 1. Circulating malondialdehyde negatively correlated with the bacterial load of the spleen. Although the number of TNFα transcripts in circulating peripheral blood mononuclear cells did not differ, peripheral blood mononuclear cells isolated from group 2 at 48 hours produced much greater concentrations of tumor necrosis factor-α after stimulation with Pam3Cys. In parallel, the apoptosis rate of circulating monocytes was increased in group 2 at 48 hours. Lung myeloperoxidase activity at 24 hours, serving as indirect evidence of neutrophil infiltration, was decreased in group 2.

Conclusions: Recombinant human interferon-γ administration prolonged survival in rabbits with experimental E. coli urosepsis. Its action was probably related to increased bacterial phagocytosis after modulation of oxidant status and reversal of monocyte immunoparalysis.

Keywords: Escherichia coli; immunomodulation; interferon-gamma; kidney; pyelonephritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Escherichia coli Infections / drug therapy*
  • Immunomodulation
  • Interferon-gamma / therapeutic use*
  • Male
  • Pyelonephritis / drug therapy*
  • Pyelonephritis / microbiology*
  • Rabbits

Substances

  • IFNG protein, human
  • Interferon-gamma